The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Open accessAbstract
Significance: Emerging evidence indicates patients who benefit from antiangiogenic therapies have improved vessel function. To determine how bevacizumab modulates vessel morphology to improve vessel function we conducted a phase II trial of preoperative bevacizumab followed by bevacizumab combined with chemotherapy in HER2-negative breast cancer patients. Our results suggest that the clinical response to bevacizumab may occur through an increase in the extent of vascular normalization primarily in patients with a high baseline tumor microvessel density. If validated, these observations suggest approaches to improve antiangiogenic therapy and to identify patients likely to benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the dose and schedule of anti-VEGF agents might need to be tailored to baseline levels of tumour vascularity78 and/or VEGF.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165 · cited 2×
“Breast Cancer Res Treat 125(3):687–696.”
BackgroundWillett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966 · cited 1×
“Nonetheless, the magnitude of the decrease in IFP was less than that seen in rectal cancer (20, 22), which may indicate that either BC vessels are less sensitive to VEGF blockade or bevacizumab distribution in BC tissue is limited.”
BackgroundSelf-citationBatchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Self-citationMeasurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6823 · Cited by 1,654
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 3×
“, pancreatic ductal adenocarcinoma), strategies that increase perfusion without pruning—targeting alternative angiogenic pathways (46), directly inducing differentiation of intratumoral sources of pericyte progenitors (47), and increasing vessel patency by reducing solid stress (31–33) or enhancing lumen formation (48…”
BackgroundSelf-citationKuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.460 · Cited by 1,330 · cited 1×
“Moreover, a favorable pathologic response to neoadjuvant therapy is associated with longer diseasefree survival (4, 5).”
Background
Research works printed but not linked: 1
- D Foernzler Tumor tissue based biomarker analysis in NO16966: A randomized phase III study of first-line bevacizumab in combination with oxaliplatin-based chemotherapy in patients with mCRC. ASCO Gastrointestinal Cancers Symposium (abstr 374). Available at meetinglibrary.asco.org/content/2207-72. (2010).
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationTherapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
“As an alternative, both preclinical and clinical studies indicated that careful dosing of antiangiogenic therapies could favor vessel normalization, resulting in a better patient outcome (226, 227).”
Tumor angiogenesis and vascular normalization: alternative therapeutic targets
Viallard, C., & Larrivée, B. (2017) · Angiogenesis · doi:10.1007/s10456-017-9562-9 · Cited by 1,424
“Careful dosage of VEGF inhibitors can restore levels of angiogenic signals in tumors, leading to decreased permeability by tightening cell–cell junctions and by actively recruiting pericytes, resulting in increased tumor perfusion [103].”
BackgroundAntiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 828
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
“Functionally, vascular normalization reduces hypoxia and increases the delivery and efficacy of cytotoxic agents [25, 33, 151].”
Self-citation
Metadata
- Authors
- Tolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., Yeh, E. D., Jain, S. R., Golshan, M., Brock, J., Snuderl, M., Winer, E. P., Krop, I. E., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2015-11-02
- Volume
- 112
- Issue
- 46
- Pages
- 14325-14330
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4655544
- OpenAlex
- W1921704765
- Cited by
- 258
- References
- 59
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 17 · 2023: 19 · 2022: 34 · 2021: 33 · 2020: 20 · 2019: 35 · 2018: 21 · 2017: 31 · 2016: 20
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, other-oa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- Genentech (Gen24357)
- HHS | NIH | National Cancer Institute (2P50 CA089393-08S2, R01CA098706)
- U.S. Department of Defense (W81XWH-10-1-0016)
- Susan G. Komen for the Cure (PDF14301739)
- Associazione Italiana per la Ricerca sul Cancro (13604)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- bevacizumab, breast cancer, neoadjuvant chemotherapy, microvessel density, vascular normalization, interstitial fluid pressure, triple-negative breast cancer, HER2-negative breast cancer, pathological complete response, predictive biomarkers, basal-like breast cancer, hormone receptor-positive breast cancer
- MeSH terms
- Bevacizumab, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Middle Aged, Neovascularization, Pathologic, Biomarkers, Tumor, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. https://app.cochat.ai/papers/10.1073/pnas.1518808112
- The paper
- Tolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., Yeh, E. D., Jain, S. R., Golshan, M., Brock, J., Snuderl, M., Winer, E. P., Krop, I. E., & Jain, R. K. (2015). Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1518808112
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.